Printer Friendly

FDA advisory on nevirapine.

On January 19, 2005, the FDA issued a public health advisory recommending against starting ongoing nevirapine treatment in women with a CD4 count greater than 250, unless benefits clearly outweigh risks. Both men and women (but especially women) with a high CD4 count are at greater risk of liver toxicity from nevirapine than those with more advanced HIV disease. This warning is not new; the manufacturer Boehringer Ingelheim warned about the same liver risk in February 2004. The new advisory reflects recent changes to the package insert, and also provides an excellent short summary on risks and benefits of nevirapine. The FDA noted that "serious and fatal liver toxicity has not been reported alter single doses of nevirapine" (used to prevent mother-to-infant HIV transmission during childbirth)--and that "symptomatic liver toxicity has not been reported in HIV-infected children, and nevirapine is available in a liquid formulation while many other antiretrovirals are not."

The FDA advisory is at
COPYRIGHT 2005 John S. James
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:AIDS Treatment News
Article Type:Brief Article
Geographic Code:1USA
Date:Jan 28, 2005
Previous Article:Global good news: many more treated.
Next Article:Conferences and meetings calendar, 2005.

Related Articles
Nevirapine (VIRAMUNE [R]) Strengthens Warning on Liver, Skin Toxicities.
Tenofovir: FDA Hearing on Important New Antiretroviral.
Nevirapine court battle moves favourably for HIV positive women.
Nevirapine patient assistance program: Model for better administration?
Nevirapine results quickly put into practice.
Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less cost.
Clinton Foundation gets big price reduction--40 cents a day for three-drug combination.
Nevirapine precautions published.
Nevirapine misinformation: will it kill?
Adult HIV treatment guidelines updated.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters